Aceragen, Inc.: Nasdaq/NYSE listing notice — Aceragen receives Nasdaq deficiency notice for late Q1 10-Q filing

Aceragen, Inc.

Received Nasdaq notice on May 24, 2023 for failure to file Form 10-Q for period ended March 31, 2023.
Company has until July 24, 2023 to submit a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1).
If plan accepted, Nasdaq may grant extension until November 20, 2023 to file the delinquent report.
Notice does not immediately affect listing or trading of ACGN common stock.
Company intends to submit a compliance plan if filing not made by July 24.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Aceragen, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

May 24, 2023, Aceragen, Inc. (the “Company”) received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company had not yet filed its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. The Notice states that the Company has until July 24, 2023 to submit to Nasdaq a plan to regain compl

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-23-066071

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.